Replies to post #16628 on NDT Pharmaceuticals Inc (NDTP)

[Ecomike]

SEC reqs about the 15-12g filing that have protected the shell for 11 years while it was quiet, require Hovis and any other officers and directors to stay silent until the company is fully reporting again, either by re-registering the shares with the SEC and going back to fully reporting, or by using the Alt-filing method with the OTC.

But no new shares, like the shares the CCA, LLC folks will soon swap for CCA, LLC shares/Biotech assets, can only be registered and sold no sooner than a year later after and until they go back to fully reporting with the SEC S-1/1-A filing first, and then its a year before they could sell any of their shares to retail, meaning the 290,000 share float is all there is for this beast for a year starting the day they go back to fully reporting.

Until then they in a gagged, quiet, unable to talk legally, quite period. To talk to us and tell us "when the lights go on and how" before they are SEC current would risk the SEC suspending trading and sending us to grey sheets.

It is the price we pay for getting in early.

Only reason we have any clue what is coming, is because the Court-Judge appointed Custodian had to notify shareholders of the shareholder meeting and checklist of items to be approved at that meeting, in which the CCA, LLC R/M was the only item on a list of almost 10 things they were going to approve at that shareholder meeting.

My DD and digging is how we found out what was inbound, because CCA, LLC, a private Biotech, had filed an SEC filing in 2016 that disclosed what they have and who they are.

That shareholder letter in October last year, also confirmed they still had the UPennMed Research Joint Venture, joint ownership deal between the firm (CCA, LLC) R/M with Milv to form NDTP.

So no, in fact if they were telling us anything, I would be freaking out selling fast during this dark period.

The fact they are and have been, have stayed gagged all this time tells me this is not a scam, and tells me it is real.

What news we have seen/found the hard way was public filings with OTCmarkets and the Nevada SOS (Listing the CEO, James Hovis, and the company attorney that a search tells us is a specialist in SEC S-1/1-A filings (BINGO Baby), FINRA-ticker and Name change, and stuff we mined the hard way like finding the web site registered to one of the CCA, LLC major shareholders.

This is as good as it gets at this stage.

[Ecomike]

IMHO, NDTP/CCA,LLC/UPennMed's JV product(s) my be on the market in weeks, if not months and the License-able Biotech may already be in NDA-confidential negotiations with 300 Bil dollar drug firms like Novartis.

If I am right, we will not know until it is too late, just like the Kodak News that rallied the stock 200% in one day on a Gift form the US Gov last week, of over 500 Mil dollars to save Kodak from BK, and that put them in the business overnight night of making generic drug components for the US Gov.

I gave up my Kodak stock way too soon. Last week's Kodak news was not on my bingo card. NDTP is on my bingo card, the whole page is NDTP.

LOL

What if UPennMed is funding and getting shares in NDTP for their part of the CCA, LLC UPennMed JV Biotech assets????

Just a thought, but it is also on my "possible" Bingo card.

If that happens, if I am right and that happens, it will add huge credibility to the tech and NDTP stock value.

The second largest largest shareholder of the firm R/M here is also a director of the UPennMed research Hospital Trust that manages UPennMed IP=Patent and research assets and they are a 50/50 partner with CCA, LLC the form Hovis runs, as he now runs NDTP.

There are only three dots to connect, UPennMed-NDTP-CCA,LLC and Hovis runs two of them, and Mathias is number II on the CCA, LLC list and he is a director of the UPennMed Trust.

They are running out of things on the to list, just a Huge SEC filing left now to confirm what we know is coming, and has arrived.

[Ecomike]

$NDTP , we know from the shareholder letter, the Nevada SOS updates, 12 years of fees paid to the Nevada SOS and the company naming Hovis the CEO/Director in Late May, and from the OTCmarkets updates who the CEO is, James Hovis, the same person Running CCA, LLC and the attorney doing the SEC package, S-1/1-A, and all of those tell us the Private Biotech CCA, LLC is merging with the old Milv (now known as NDTP ) shell, already renamed NDTP for Nano Delivery Technology Pharmaceuticals Inc.

We know who the founders (2013), founding shareholders of CCA, LLC are, we know they are and have been Building a Billion dollar Biotech, and we know they have been been partnered with the University of Pennsylvania's Medical University Research Hospital's Traumatic Brain Injury teams and they have been successfully testing the soon to be NDTP, BBB-Blood Brain Barrier crossing nano-particle complex (liposome tech) oral IV drink line capable non drug technology that could hit the streets running as drink line, meaning almost immediate revenue.

And Licensing to big Biotechs for use to carry Rx drugs, already approved, for delivery to the brain.....

The float is only 290,000 shares. At $3/share that is $870,000 float,

The news I expect to see will reveal a billion dollar Biotech and billion dollar drink line IMHO.

Going from $870,000 to 1 Billion dollars is a 1000X jump! That means $3/share could see $3000/share.

But we also know the CCA, LLC folks will get shares, and any cash raised (If not already done with CCA, LLC shares ) will add to the OS.

So assume the OS goes from 450,000 to 4,500,000 shhares, a 10X increase.

Then $3000/share becomes a $300/share potential price target

Massive upside potential, and almost zero down side potential.

The stock already traded at $10 to $10.60/share twice.

Selling shares down here is just foolish IMHO.